Premium
Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI‐CPTC initiative perspective
Author(s) -
Rodriguez Henry,
Rivers Robert,
Kinsinger Christopher,
Mesri Mehdi,
Hiltke Tara,
Rahbar Amir,
Boja Emily
Publication year - 2010
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201000057
Subject(s) - proteomics , biomarker discovery , biomarker , proteome , computational biology , cancer biomarkers , personalized medicine , quantitative proteomics , cancer , bioinformatics , medicine , biology , biochemistry , gene
Proteomics holds great promise in personalized medicine for cancer in the post‐genomic era. In the past decade, clinical proteomics has significantly evolved in terms of technology development, optimization and standardization, as well as in advanced bioinformatics data integration and analysis. Great strides have been made for characterizing a large number of proteins qualitatively and quantitatively in a proteome, including the use of sample fractionation, protein microarrays and MS. It is believed that differential proteomic analysis of high‐quality clinical biospecimen (tissue and biofluids) can potentially reveal protein/peptide biomarkers responsible for cancer by means of their altered levels of expression and/or PTMs. Multiple reaction monitoring, a multiplexed platform using stable isotope dilution‐MS with sensitivity and reproducibility approaching that of traditional ELISAs commonly used in the clinical setting, has emerged as a potentially promising technique for next‐generation high‐throughput protein biomarker measurements for diagnostics and therapeutics.